LAB Research announces the closing of its rights offering

LAB Research Inc. ("LAB Research" or the "Company") (TSX: LRI), a Canadian-based global non-clinical contract research organization, today announced the successful closing of its previously announced rights offering (the "Rights Offering") for total gross proceeds of $14.2 million.

A total of 34.6 million common shares of the Company were issued as part of the transaction including 18.3 million common shares issued to the Solidarity Fund QFL (the "Fund"). Following the closing of the Rights Offering, the Fund's ownership position in LAB Research common shares has increased from 18% to 41%. Pursuant to an agreement between the Company and the Fund and subject to maintaining a predetermined ownership position, the Fund will be able to nominate two individuals on LAB Research's Board of Directors. The total issued and outstanding common shares of the Company now add up to 52.7 million.

The net proceeds of the Rights Offering will be used i) for the repayment of a bridge loan from the Fund for $0.5 million; ii) to complete the installation of inhalation toxicology equipment for our Canadian site for $2.4 million; and iii) to reduce the Company's long-term debt in Canada by $5 million. The remainder of the proceeds will be used for working capital purposes.

"We are extremely pleased with the interest demonstrated towards our Rights Offering. The success of the transaction demonstrates the favourable market reaction to the progress made by LAB Research in addressing all issues that negatively impacted our Company over the last 12 months. The closing of the Rights Offering also confirms the good standing of our Canadian bank covenants. With the Rights Offering almost fully subscribed, we now have sufficient liquidities to start accelerating the deleveraging of our balance sheet and finance our growing operations as activity is picking up in each of our three sites." commented Mr. Luc Mainville, President and Chief Executive Officer of LAB Research. "We are now better positioned than ever to reap the full rewards of the recently completed sites and services expansions." added Mr. Mainville.

Following the closing of the Rights Offering, the Company will proceed with the issuance of 2.5 million options to staff, management and Board of Directors representing 7.1% of the common shares issued in the Rights Offering. The option grant aims at ensuring the proper incentive program to key participants in the future growth of the Company.

Source: LAB RESEARCH INC.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Patient-derived organoids: Transforming cancer research and personalized medicine